The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales

Objective:To obtain information on the use of single antigen measles, mumps and rubella vaccines to improve estimates of population immunity and help predict outbreaks.Design:We requested information from providers of single antigen vaccines and from the Medicine and Healthcare products Regulatory A...

Full description

Saved in:
Bibliographic Details
Published inArchives of disease in childhood Vol. 92; no. 9; pp. 786 - 789
Main Authors Sonnenberg, Pam, Crowcroft, Natasha S, White, Joanne M, Ramsay, Mary E
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health 01.09.2007
BMJ
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
BMJ Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective:To obtain information on the use of single antigen measles, mumps and rubella vaccines to improve estimates of population immunity and help predict outbreaks.Design:We requested information from providers of single antigen vaccines and from the Medicine and Healthcare products Regulatory Agency on requests for importation of single antigen measles and mumps vaccines.Setting:England and Wales.Main outcome measures:Number of doses of single measles, mumps and rubella vaccine, by age of child (in months), year given and area of residence, and number of children who have received all three single vaccinations.Results:Of 27 providers identified, 13 held single site clinics: nine were individual general practitioners and five held clinics at multiple sites. Data were received from 9/27 (33%) providers operating 40/74 (54%) clinic sites. We received information on 60 768 vaccinations administered by single vaccine providers and 269 917 doses requested for importation. For children born in 2001/2002, the minimum estimates for the proportion who received single measles vaccine are 1.7% in 2001 and 2.1% in 2002, with a reasonable maximum estimate of 5.6% over the 2 years. For single mumps vaccine, the minimum estimates are 0.3% in 2001 and 0.02% in 2002, with a maximum estimate of 4.0%.Conclusion:The contribution of single vaccines to immunity is small in comparison to that of the combined measles, mumps and rubella vaccine (MMR). For recent birth cohorts this contribution could increase routine coverage for measles-containing vaccines by around 2%, still below the level of immunity required to sustain elimination.
Bibliography:istex:36E81A4EDFFBFACCBF59F5A1E6364357F7BCC4F4
PMID:17412744
ArticleID:ac109223
ark:/67375/NVC-DJB3P1SX-1
href:archdischild-92-786.pdf
local:archdischild;92/9/786
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0003-9888
1468-2044
DOI:10.1136/adc.2006.109223